Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Theragenics (TGX) on the up and up -- Ignore unavailable to you. Want to Upgrade?

To: bill hopkins who wrote (873)	6/18/1998 12:55:00 PM
From: Ron Kline	Read Replies (1) \| Respond to of 1055

This is good news to have Christine taking over as chairman since I think she has the ability to move THRX to the next level. THRX is basing nicely and should breakout again once the market comes back. NORCROSS, Ga.--(BUSINESS WIRE)--June 18, 1998--Theragenics Corp. (NASDAQ:THRX - news), the Atlanta-based cancer treatment producer, today announced that in the June 13, 1998 meeting of the Board of Directors, Christine Jacobs was named Chairman succeeding Charles Klimkowski. Klimkowski served as Chairman since 1994 and will remain on the board as a director. Upon assuming her new position Jacobs thanked Klimkowski for his dedication and leadership over the past 4 years. Jacobs went on to say, ''Charles has greatly contributed to the success of Theragenics during his term as Chairman. His decision to remain on the board as a director and make his experience available to me will be a benefit as I help usher the Company into its next phase of growth.'' M. Christine Jacobs joined Theragenics Corp. in 1987. Prior to becoming CEO in 1993, Jacobs held the positions of President, Chief Operating Officer, Vice President of Sales and Marketing and Director of Marketing and Sales. A Theragenics Director since 1992, Jacobs also serves on the board of directors of HBO & Company and the Board of Councilors of the Carter Center in Atlanta. Additional memberships include the Association for Corporate Growth, The American Brachytherapy Society, 1997 Entrepreneur of the Year in the Health Care Turnaround category for the Southeast Region, Georgia Bio-Medical Partnership, the Georgia Chamber of Commerce, the Secretary of State's Small Business Taskforce and The Executive Committee (TEC). Commenting on Jacobs' new position, Klimkowski said, ''Chris has been a valuable asset to the Company and a key reason for its outstanding growth. Chris possesses a highly desirable set of skills and experiences that along with her drive and determination make a clear choice to guide Theragenics over the next several years. I am delighted she has agreed to accept the Chairmanship of Theragenics.'' Theragenics Corporation, based in Norcross, Ga., is the manufacturer of TheraSeed(R) - palladium-103, a rice-sized radioactive device used in the treatment of localized prostate cancer with a one-time, minimally invasive procedure. For additional information on the Company call Theragenics' Investor Relations Department at (800) 998-8479. The Company's common stock is traded on the NASDAQ stock exchange under the symbol THRX.